Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age?

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that might affect up to one-third of the adult population in industrialised countries. NAFLD incorporates histologically and clinically different non-alcoholic entities; fatty liver (NAFL, steatosis hepatis) and steatohepatitis (NASH-characterised by hepatocyte ballooning and lobular inflammation ± fibrosis) might progress to cirrhosis and rarely to hepatocellular cancer. NAFL increasingly affects children (paediatric prevalence is 4.2%-9.6%). Type 2 diabetes mellitus (T2DM), insulin resistance (IR), obesity, metabolic syndrome and NAFLD are particularly closely related. Increased hepatic lipid storage is an early abnormality in insulin resistant women with a history of gestational diabetes mellitus. The accumulation of triacylglycerols in hepatocytes is predominantly derived from the plasma non-esterified fatty acid pool supplied largely by the adipose tissue. A few NAFLD susceptibility gene variants are associated with progressive liver disease, IR, T2DM and a higher risk for hepatocellular carcinoma. Although not approved, pharmacological approaches might be considered in NASH patients.

Original languageEnglish
Pages (from-to)9072-9089
Number of pages18
JournalWorld Journal of Gastroenterology
Issue number27
DOIs
Publication statusPublished - Jul 21 2014

Fingerprint

Type 2 Diabetes Mellitus
Liver Diseases
Fatty Liver
Insulin Resistance
Hepatocytes
Fibrosis
Disease Resistance
Gestational Diabetes
Disease Susceptibility
Liver Neoplasms
Developed Countries
Adipose Tissue
Hepatocellular Carcinoma
Triglycerides
Chronic Disease
Fatty Acids
Obesity
Pharmacology
Insulin
Pediatrics

Keywords

  • Dysfunctional adipose tissue
  • Genetics
  • Hepatocellular cancer
  • Insulin resistance
  • Liver cirrhosis
  • Non-alcoholic fatty liver disease
  • Non-alcoholic steatohepatitis
  • Obesity
  • Therapy
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Non-alcoholic fatty liver disease and type 2 diabetes mellitus : The liver disease of our age? / Firneisz, G.

In: World Journal of Gastroenterology, No. 27, 21.07.2014, p. 9072-9089.

Research output: Contribution to journalArticle

@article{068e8a1fec4d4d4fb28ef2453d9d0f06,
title = "Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age?",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that might affect up to one-third of the adult population in industrialised countries. NAFLD incorporates histologically and clinically different non-alcoholic entities; fatty liver (NAFL, steatosis hepatis) and steatohepatitis (NASH-characterised by hepatocyte ballooning and lobular inflammation ± fibrosis) might progress to cirrhosis and rarely to hepatocellular cancer. NAFL increasingly affects children (paediatric prevalence is 4.2{\%}-9.6{\%}). Type 2 diabetes mellitus (T2DM), insulin resistance (IR), obesity, metabolic syndrome and NAFLD are particularly closely related. Increased hepatic lipid storage is an early abnormality in insulin resistant women with a history of gestational diabetes mellitus. The accumulation of triacylglycerols in hepatocytes is predominantly derived from the plasma non-esterified fatty acid pool supplied largely by the adipose tissue. A few NAFLD susceptibility gene variants are associated with progressive liver disease, IR, T2DM and a higher risk for hepatocellular carcinoma. Although not approved, pharmacological approaches might be considered in NASH patients.",
keywords = "Dysfunctional adipose tissue, Genetics, Hepatocellular cancer, Insulin resistance, Liver cirrhosis, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Obesity, Therapy, Type 2 diabetes mellitus",
author = "G. Firneisz",
year = "2014",
month = "7",
day = "21",
doi = "10.3748/wjg.v20.i27.9072",
language = "English",
pages = "9072--9089",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "27",

}

TY - JOUR

T1 - Non-alcoholic fatty liver disease and type 2 diabetes mellitus

T2 - The liver disease of our age?

AU - Firneisz, G.

PY - 2014/7/21

Y1 - 2014/7/21

N2 - Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that might affect up to one-third of the adult population in industrialised countries. NAFLD incorporates histologically and clinically different non-alcoholic entities; fatty liver (NAFL, steatosis hepatis) and steatohepatitis (NASH-characterised by hepatocyte ballooning and lobular inflammation ± fibrosis) might progress to cirrhosis and rarely to hepatocellular cancer. NAFL increasingly affects children (paediatric prevalence is 4.2%-9.6%). Type 2 diabetes mellitus (T2DM), insulin resistance (IR), obesity, metabolic syndrome and NAFLD are particularly closely related. Increased hepatic lipid storage is an early abnormality in insulin resistant women with a history of gestational diabetes mellitus. The accumulation of triacylglycerols in hepatocytes is predominantly derived from the plasma non-esterified fatty acid pool supplied largely by the adipose tissue. A few NAFLD susceptibility gene variants are associated with progressive liver disease, IR, T2DM and a higher risk for hepatocellular carcinoma. Although not approved, pharmacological approaches might be considered in NASH patients.

AB - Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that might affect up to one-third of the adult population in industrialised countries. NAFLD incorporates histologically and clinically different non-alcoholic entities; fatty liver (NAFL, steatosis hepatis) and steatohepatitis (NASH-characterised by hepatocyte ballooning and lobular inflammation ± fibrosis) might progress to cirrhosis and rarely to hepatocellular cancer. NAFL increasingly affects children (paediatric prevalence is 4.2%-9.6%). Type 2 diabetes mellitus (T2DM), insulin resistance (IR), obesity, metabolic syndrome and NAFLD are particularly closely related. Increased hepatic lipid storage is an early abnormality in insulin resistant women with a history of gestational diabetes mellitus. The accumulation of triacylglycerols in hepatocytes is predominantly derived from the plasma non-esterified fatty acid pool supplied largely by the adipose tissue. A few NAFLD susceptibility gene variants are associated with progressive liver disease, IR, T2DM and a higher risk for hepatocellular carcinoma. Although not approved, pharmacological approaches might be considered in NASH patients.

KW - Dysfunctional adipose tissue

KW - Genetics

KW - Hepatocellular cancer

KW - Insulin resistance

KW - Liver cirrhosis

KW - Non-alcoholic fatty liver disease

KW - Non-alcoholic steatohepatitis

KW - Obesity

KW - Therapy

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84905381294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905381294&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i27.9072

DO - 10.3748/wjg.v20.i27.9072

M3 - Article

C2 - 25083080

AN - SCOPUS:84905381294

SP - 9072

EP - 9089

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 27

ER -